On the earnings call for its 2027 fiscal second quarter, ended Sept. 30, held on Oct. 23, 2026, Dr. Reddy's (NYSE:RDY) announced that its underlying base business delivered double-digit growth. For long-term investors, the company's ability to expand core geographic markets provides stability while high-value generic launches clear regulatory hurdles. Three takeaways from management on the call highlight where the business is headed. Management resolved active pharmaceutical ingredient (API, the biologically active component in a drug) scale-up challenges for Semaglutide, a diabetes and weight-loss medication. The company plans to reload supplies across Canada, Latin America, and Africa by November of 2026. Consolidated revenue fell 1.5% year over year to $905 million due to reduced sales of Lenalidomide, a blood cancer medication. Strong demand in India and emerging markets cushioned the decline, helping sustain gross margins at 52.1%.
CryptoAlerta — análise de criptomoedas e mercado em tempo real